Stay updated on Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial

Sign up to get notified when there's something new on the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The page has removed a significant publication reference regarding the 4-year results of a phase 3 trial comparing adjuvant nivolumab and ipilimumab for melanoma, which is a core aspect of the content.
    Difference
    0.2%
    Check dated 2025-05-15T19:26:26.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    19 days ago
    Change Detected
    Summary
    The page has been updated to reflect new data regarding the safety and tolerability of Nivolumab and Ipilimumab, with a significant increase in the duration of study from up to 60 months to up to 106.6 months. Additionally, the location has changed from Fridley, Minnesota to Robbinsdale, Minnesota.
    Difference
    1.0%
    Check dated 2025-05-01T05:12:34.000Z thumbnail image
  4. Check
    26 days ago
    No Change Detected
  5. Check
    33 days ago
    Change Detected
    Summary
    The page has undergone significant content changes, including the removal of detailed study information regarding a clinical trial for melanoma and the addition of a new revision number and collaborators.
    Difference
    5%
    Check dated 2025-04-16T14:32:12.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.1%
    Check dated 2025-04-09T09:19:51.000Z thumbnail image
  7. Check
    48 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.1%
    Check dated 2025-04-01T23:15:37.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    0.9%
    Check dated 2025-02-24T20:48:11.000Z thumbnail image

Stay in the know with updates to Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page.